StockData
Sangamo Therapeutics, Inc logo

Sangamo Therapeutics, Inc (SGMOQ) company profile

SGMOQOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q1 năm tài chính 2026, quý kết thúc ngày Mar 31, 2026Last filing: 10-Q on May 14, 2026Score 4/30
$0.10−0.01 (-8.17%)

Close on Oct 19, 2026Market cap $39.43MP/E –Yield –

About Sangamo Therapeutics

Biological Products, (No Diagnostic Substances), SIC 2836

Sangamo Therapeutics, Inc. is a biotechnology company that researches and develops genomic medicines and gene therapy product candidates. The company focuses on developing therapies utilizing its zinc finger technology platform, zinc finger transcriptional regulators, and capsid delivery technologies. Its clinical-stage and core preclinical programs include development candidates for rare genetic conditions and neurological indications, such as isaralgagene civaparvovec for Fabry disease and a hemophilia A program. Sangamo targets patients with genetic and neurodevelopmental conditions and works directly with major pharmaceutical and biotechnology partners, licensing its technology assets and collaborating on clinical development.

The company operates out of principal executive offices and facilities located in Richmond, California, and maintains additional office and laboratory facilities in Brisbane, California. Sangamo also conducted restructuring activities involving operations in France. It partners globally with multinational pharmaceutical companies across the United States and international markets.

Summary of the business section of Sangamo Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Sangamo Therapeutics, Inc
Founded
1995
Headquarters
Richmond, CA
Address
501 Canal Blvd. 94084
Phone
(510) 970-6000
Employees
142, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst& Young LLP, San Mateo, California

Stock & identifiers

Ticker
SGMOQ
Former tickers
SGMO until Oct 27, 2026
Exchange
OTC
IPO date
Apr 6, 2000
Shares outstanding
414M, May 11, 2026
Public float
$152.67M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1001233
CUSIP
800677106
ISIN
US8006771062
FIGI
BBG000BHYT80
Share class FIGI
BBG001S95JZ2
LEI
2549006WMRKRC4G32Z67
EIN
68-0359556

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Sandy MacraePRESIDENT, CEO AND DIRECTOR1,895,043
Nikunj JainPrincipal Accounting Officer235,292
Gregory D. DavisHead of Research & Technology113,654
Nathalie Dubois-StringfellowSVP-CHIEF DEVELOPMENT OFFICER328,733
Scott B. WilloughbySVP, CHIEF LEGAL OFFICER, SECY647,370
Prathyusha DuraibabuPRINCIPAL FINANCIAL OFFICER660,042
Robert CareyDirector99,600
Margaret A. HornDirector82,650
Kenneth J. HillanDirector99,600
Karen L. SmithDirector102,100
James R. MeyersDirector99,600
Courtney BeersDirector82,650
H. Stewart ParkerDirector112,600
John MarkelsDirector96,384

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2024$2.46M$3.97M$1.15M$14–
FY2023$2.39M-$340.20K$1.04M$7–
FY2022$4.81M$967.86K$1.47M$42–
FY2021$4.74M-$1.61M$1.27M$90$126
FY2020$3.84M$9.63M$1.70M$186$126

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2024

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsIncentive payOtherTotalvs. prior year
Alexander D. Macrae
Chief Executive Officer
$716.37K$909.40K$825.25K$6.43K$2.46M+3%
Nathalie Dubois-Stringfellow
Chief Development Officer
$453.60K$323.97K$348.37K$6.43K$1.13M+10%
Prathyusha Duraibabu
Chief Financial Officer
$483.96K$323.97K$371.68K$6.43K$1.19M+12%
Scott B. Willoughby
Chief Legal Officer & Corporate Secretary (5)
$457.80K$323.97K$351.59K$6.43K$1.14M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of March 27, 2026, we had 142 full time employees located in the United States and the United Kingdom.”

Corporate history

Events identified from SEC filings

DateEventDetails
Oct 7, 2026DelistingNotice of delisting from exchange (Form 25)
Sep 21, 2026Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 21, 2026BankruptcyBankruptcy or receivership (8-K Item 1.03)
Sep 8, 2026Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 8, 2026BankruptcyBankruptcy or receivership (8-K Item 1.03)
Aug 28, 2026BankruptcyBankruptcy or receivership (8-K Item 1.03)
Aug 17, 2026Late filingNotification of late filing
Jul 20, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 20, 2026BankruptcyBankruptcy or receivership (8-K Item 1.03)
Jul 1, 2026Auditor changeChange in certifying accountant (8-K Item 4.01)
Jun 23, 2026BankruptcyBankruptcy or receivership (8-K Item 1.03)
Apr 29, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 29, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 6, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 30, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 6, 2018Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jan 6, 2017Name changeName changed from SANGAMO BIOSCIENCES INC to Sangamo Therapeutics, Inc
Oct 7, 2013Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Dec 28, 2006Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)

See a number that looks wrong?